Cargando…

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’

Detalles Bibliográficos
Autor principal:	Bravo, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808019/ https://www.ncbi.nlm.nih.gov/pubmed/29149108 http://dx.doi.org/10.1038/bjc.2017.342

Ejemplares similares

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
por: Willmann, Jonas, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
por: Marvaso, Giulia, et al.
Publicado: (2021)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience
por: Oehler, Christoph, et al.
Publicado: (2019)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
por: Li, Shuai, et al.
Publicado: (2019)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
por: Berber, Tanju, et al.
Publicado: (2022)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy
por: Wray, Justin, et al.
Publicado: (2017)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer
por: Kim, Daniel W., et al.
Publicado: (2019)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review
por: Yan, Bernie, et al.
Publicado: (2023)

Hepatocellular Carcinoma in the COVID‐19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?
por: Scorsetti, Marta, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
por: Lu, Shao-Lun, et al.
Publicado: (2016)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pad439qquu4hqaq5ordipahlrs